Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Baxter
Boehringer Ingelheim
Moodys
McKinsey

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Dovitinib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Dovitinib: Sponsors, patents, clinical trial progress

Dovitinib is an investigational drug.

There have been 50 clinical trials for Dovitinib. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2011.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Adenoid Cystic, and Breast Neoplasms. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and Asan Medical Center.

There are forty-five US patents protecting this investigational drug and six hundred and nineteen international patents.

Recent Clinical Trials for Dovitinib
TitleSponsorPhase
Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic CarcinomaSeoul National University HospitalPhase 2
Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoPhase 2
Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic CancerNational Cancer Institute (NCI)Phase 1

See all Dovitinib clinical trials

Clinical Trial Summary for Dovitinib

Top disease conditions for Dovitinib
Top clinical trial sponsors for Dovitinib

See all Dovitinib clinical trials

US Patents for Dovitinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Dovitinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Dovitinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Dovitinib   Start Trial Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Dovitinib   Start Trial Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide Loxo Oncology, Inc. (Stamford, CT)   Start Trial
Dovitinib   Start Trial Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Dovitinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Dovitinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Dovitinib

Drugname Country Document Number Estimated Expiration Related US Patent
Dovitinib Australia 2016291676 2035-07-16   Start Trial
Dovitinib Brazil 112018000808 2035-07-16   Start Trial
Dovitinib Canada 2992586 2035-07-16   Start Trial
Dovitinib Chile 2018000119 2035-07-16   Start Trial
Dovitinib China 108349969 2035-07-16   Start Trial
Dovitinib Eurasian Patent Organization 201890318 2035-07-16   Start Trial
Dovitinib European Patent Office 3322706 2035-07-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Baxter
Harvard Business School
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.